Pfizer will buy Anacor Pharmaceuticals in a deal valued at $5.2 billion, for access to Anacor's non-steroidal topical gel to treat eczema. » Read More
Swine Flu: global pandemic or paranoia? President Obama said the health emergency declaration was merely a prudent measure. But many pharmaceutical stocks were sharply higher Monday in reaction to flu outbreaks — and the gains seemed to ripple through the sector.
Following are the “Fast & Furious” trades - hot ways to play tomorrow's market moving events. Also you'll find the gang's "Final Trades" here.
Stocks ended higher Friday after better-than-expected results from Ford but ended lower for the week, snapping a six-week winning streak. recovered Friday after a drop triggered by the release of the bank stress-test results.
As stocks capped a seventh consecutive week of gains, traders Marty Cunningham of Solazzo Trading Company and Michael Gurka of First Street Capital Partners considered how much room remains for the rally.
At Pfizer's annual shareholder meeting in Atlanta this morning, investors approved a version of "Say on Pay."
CNBC’s Mike Huckman is keeping a close eye on Big Pharma earnings. And he suggests you do the same - because he's spotted a devil the details.
Not a surprise, but my post yesterday on what one reader called the analyst "flip-flop" on Dendreon generated a lot of responses and queries.
In this Web Extra, Pete Najarian talks Pharma takeovers. What's on his radar?
Following are the day’s biggest winners and losers. Find out why shares of Yum! Brands and Piper Jaffray popped while Microsoft and Abbott Labs dropped.
Oh, the fun the late-night comics could have with this one. The makers of the little blue pill are a little red-faced on the Emerald Isle.
With stocks rallying for 5 weeks in a row now, dividend yields are falling back to Earth. The average dividend yield of the Dow 30 has fallen over 25% since the rally began in early March. See how the 30 companies in the Dow compare.
BlackRock's Bob Doll says the investor needs to realize where we are in both the economic cycle and the market cycle, and he has some suggestions about where to re-adjust a portfolio. (Part One)
BlackRock's Bob Doll says the investor needs to realize where we are in both the economic cycle and the market cycle, and he has some suggestions about where to re-adjust a portfolio. (Part Two)
Cramer makes the call on viewers' favorite stocks.
A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.
At the start of the month, General Electric was falling fast and the company that once boasted a half trillion dollar market cap, was at risk of falling out of the Top 20 biggest companies in the S&P 500. In less than a month, that has changed significantly.
Despite the drawback in stocks this morning, Bill Spiropoulous of CoreStates Capital Advisors told CNBC that the market recovery “is in full swing” — but Joe Heider of Dawson Wealth Management said investors “can’t call the bottom” yet. Both had investment recommendations.
The Pit Boss is seeing explosive options action in a drug stock. Find out which one!
The economy may be headed toward a recovery sometime in the third or fourth quarter, said Hugh Johnson of Johnson Illington Advisors.
M&A expert Howard Lanser reveals the next sector where he expects to see a big uptick in takeovers!